Matthew B Jarpe
Overview
Explore the profile of Matthew B Jarpe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Logan R, Ozburn A, Arey R, Ketchesin K, Winquist A, Crain A, et al.
Mol Psychiatry
. 2020 Nov;
26(8):4066-4084.
PMID: 33235333
Valproate (VPA) has been used in the treatment of bipolar disorder since the 1990s. However, the therapeutic targets of VPA have remained elusive. Here we employ a preclinical model to...
2.
Ma J, Huo X, Jarpe M, Kavelaars A, Heijnen C
Acta Neuropathol Commun
. 2018 Oct;
6(1):103.
PMID: 30270813
Chemotherapy-induced cognitive impairment (CICI) is a commonly reported neurotoxic side effect of chemotherapy, occurring in up to 75% cancer patients. CICI manifests as decrements in working memory, executive functioning, attention,...
3.
Krukowski K, Ma J, Golonzhka O, Laumet G, Gutti T, van Duzer J, et al.
Pain
. 2017 Mar;
158(6):1126-1137.
PMID: 28267067
Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment. Currently, there is no Food and Drug Administration-approved treatment available. Histone deacetylase 6 (HDAC6) is...
4.
Min C, Moore N, Shearstone J, Quayle S, Huang P, van Duzer J, et al.
PLoS One
. 2017 Jan;
12(1):e0169128.
PMID: 28060870
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients...
5.
Shearstone J, Golonzhka O, Chonkar A, Tamang D, van Duzer J, Jones S, et al.
PLoS One
. 2016 Apr;
11(4):e0153767.
PMID: 27073918
Therapeutic intervention aimed at reactivation of fetal hemoglobin protein (HbF) is a promising approach for ameliorating sickle cell disease (SCD) and β-thalassemia. Previous studies showed genetic knockdown of histone deacetylase...
6.
Regna N, Vieson M, Luo X, Chafin C, Puthiyaveetil A, Hammond S, et al.
Clin Immunol
. 2015 Nov;
162:58-73.
PMID: 26604012
We sought to determine if a selective HDAC6 inhibitor (ACY-738) decreases disease in NZB/W mice. From 22 to 38weeks-of-age, mice were injected intraperitoneally with 5 or 20mg/kg of ACY-738, or...
7.
Clark L, Demarest S, Eldredge J, Jarpe M, Li Y, Simon K, et al.
J Struct Biol
. 2013 Sep;
185(2):223-7.
PMID: 23994046
A number of light and heavy chain canonical residue core redesigns were made in a therapeutic antibody (AQC2, anti-VLA1) Fab to explore the consequences to binding affinity and stability. These...
8.
Schlesinger T, Bonvin C, Jarpe M, Fanger G, Cardinaux J, Johnson G, et al.
J Biol Chem
. 2002 Jan;
277(12):10283-91.
PMID: 11782455
MEKK1, a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase, generates anti-apoptotic signaling as a full-length protein but induces apoptosis when cleaved by caspases. Here, we show that caspase-dependent cleavage of...